Global Neoantigen Cancer Vaccine Market Size, Status and Forecast 2024-2031

Report ID: 920274 | Published Date: Sep 2024 | No. of Page: 107 | Base Year: 2023 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Personalized Vaccine
        1.2.3 Off-the-shelf Neovaccines
    1.3 Market by Application
        1.3.1 Global Neoantigen Cancer Vaccine Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Neoantigen Cancer Vaccine Market Perspective (2016-2027)
    2.2 Neoantigen Cancer Vaccine Growth Trends by Regions
        2.2.1 Neoantigen Cancer Vaccine Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Neoantigen Cancer Vaccine Historic Market Share by Regions (2016-2021)
        2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Regions (2022-2027)
    2.3 Neoantigen Cancer Vaccine Industry Dynamic
        2.3.1 Neoantigen Cancer Vaccine Market Trends
        2.3.2 Neoantigen Cancer Vaccine Market Drivers
        2.3.3 Neoantigen Cancer Vaccine Market Challenges
        2.3.4 Neoantigen Cancer Vaccine Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Neoantigen Cancer Vaccine Players by Revenue
        3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2016-2021)
        3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2016-2021)
    3.2 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
    3.4 Global Neoantigen Cancer Vaccine Market Concentration Ratio
        3.4.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2020
    3.5 Neoantigen Cancer Vaccine Key Players Head office and Area Served
    3.6 Key Players Neoantigen Cancer Vaccine Product Solution and Service
    3.7 Date of Enter into Neoantigen Cancer Vaccine Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Neoantigen Cancer Vaccine Breakdown Data by Type
    4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2016-2021)
    4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2022-2027)

5 Neoantigen Cancer Vaccine Breakdown Data by Application
    5.1 Global Neoantigen Cancer Vaccine Historic Market Size by Application (2016-2021)
    5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Neoantigen Cancer Vaccine Market Size (2016-2027)
    6.2 North America Neoantigen Cancer Vaccine Market Size by Type
        6.2.1 North America Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
        6.2.2 North America Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
        6.2.3 North America Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
    6.3 North America Neoantigen Cancer Vaccine Market Size by Application
        6.3.1 North America Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
        6.3.2 North America Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
        6.3.3 North America Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
    6.4 North America Neoantigen Cancer Vaccine Market Size by Country
        6.4.1 North America Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
        6.4.2 North America Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Neoantigen Cancer Vaccine Market Size (2016-2027)
    7.2 Europe Neoantigen Cancer Vaccine Market Size by Type
        7.2.1 Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
        7.2.2 Europe Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
        7.2.3 Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
    7.3 Europe Neoantigen Cancer Vaccine Market Size by Application
        7.3.1 Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
        7.3.2 Europe Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
        7.3.3 Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
    7.4 Europe Neoantigen Cancer Vaccine Market Size by Country
        7.4.1 Europe Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
        7.4.2 Europe Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size (2016-2027)
    8.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type
        8.2.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
    8.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application
        8.3.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
    8.4 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region
        8.4.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Neoantigen Cancer Vaccine Market Size (2016-2027)
    9.2 Latin America Neoantigen Cancer Vaccine Market Size by Type
        9.2.1 Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
        9.2.2 Latin America Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
        9.2.3 Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
    9.3 Latin America Neoantigen Cancer Vaccine Market Size by Application
        9.3.1 Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
        9.3.2 Latin America Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
        9.3.3 Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
    9.4 Latin America Neoantigen Cancer Vaccine Market Size by Country
        9.4.1 Latin America Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
        9.4.2 Latin America Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size (2016-2027)
    10.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type
        10.2.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
    10.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application
        10.3.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
    10.4 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country
        10.4.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Roche
        11.1.1 Roche Company Details
        11.1.2 Roche Business Overview
        11.1.3 Roche Neoantigen Cancer Vaccine Introduction
        11.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.1.5 Roche Recent Development
    11.2 Medimmune
        11.2.1 Medimmune Company Details
        11.2.2 Medimmune Business Overview
        11.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
        11.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.2.5 Medimmune Recent Development
    11.3 Merck
        11.3.1 Merck Company Details
        11.3.2 Merck Business Overview
        11.3.3 Merck Neoantigen Cancer Vaccine Introduction
        11.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.3.5 Merck Recent Development
    11.4 Advaxis
        11.4.1 Advaxis Company Details
        11.4.2 Advaxis Business Overview
        11.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
        11.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.4.5 Advaxis Recent Development
    11.5 Agenus
        11.5.1 Agenus Company Details
        11.5.2 Agenus Business Overview
        11.5.3 Agenus Neoantigen Cancer Vaccine Introduction
        11.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.5.5 Agenus Recent Development
    11.6 Genocea
        11.6.1 Genocea Company Details
        11.6.2 Genocea Business Overview
        11.6.3 Genocea Neoantigen Cancer Vaccine Introduction
        11.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.6.5 Genocea Recent Development
    11.7 Gritstone Oncology
        11.7.1 Gritstone Oncology Company Details
        11.7.2 Gritstone Oncology Business Overview
        11.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
        11.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.7.5 Gritstone Oncology Recent Development
    11.8 Neon Therapeutics
        11.8.1 Neon Therapeutics Company Details
        11.8.2 Neon Therapeutics Business Overview
        11.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
        11.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.8.5 Neon Therapeutics Recent Development
    11.9 Nouscom
        11.9.1 Nouscom Company Details
        11.9.2 Nouscom Business Overview
        11.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
        11.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.9.5 Nouscom Recent Development
    11.10 OSE Immunotherapeutics
        11.10.1 OSE Immunotherapeutics Company Details
        11.10.2 OSE Immunotherapeutics Business Overview
        11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
        11.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.10.5 OSE Immunotherapeutics Recent Development
    11.11 Medigene
        11.11.1 Medigene Company Details
        11.11.2 Medigene Business Overview
        11.11.3 Medigene Neoantigen Cancer Vaccine Introduction
        11.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.11.5 Medigene Recent Development
    11.12 Vaccibody
        11.12.1 Vaccibody Company Details
        11.12.2 Vaccibody Business Overview
        11.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
        11.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.12.5 Vaccibody Recent Development
    11.13 Brightpath Biotherapeutics
        11.13.1 Brightpath Biotherapeutics Company Details
        11.13.2 Brightpath Biotherapeutics Business Overview
        11.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
        11.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.13.5 Brightpath Biotherapeutics Recent Development
    11.14 Geneos Therapeutics
        11.14.1 Geneos Therapeutics Company Details
        11.14.2 Geneos Therapeutics Business Overview
        11.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
        11.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
        11.14.5 Geneos Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Personalized Vaccine
    Table 3. Key Players of Off-the-shelf Neovaccines
    Table 4. Global Neoantigen Cancer Vaccine Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 5. Global Neoantigen Cancer Vaccine Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 6. Global Neoantigen Cancer Vaccine Market Size by Regions (2016-2021) & (US$ Million)
    Table 7. Global Neoantigen Cancer Vaccine Market Share by Regions (2016-2021)
    Table 8. Global Neoantigen Cancer Vaccine Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 9. Global Neoantigen Cancer Vaccine Market Share by Regions (2022-2027)
    Table 10. Neoantigen Cancer Vaccine Market Trends
    Table 11. Neoantigen Cancer Vaccine Market Drivers
    Table 12. Neoantigen Cancer Vaccine Market Challenges
    Table 13. Neoantigen Cancer Vaccine Market Restraints
    Table 14. Global Neoantigen Cancer Vaccine Revenue by Players (2016-2021) & (US$ Million)
    Table 15. Global Neoantigen Cancer Vaccine Market Share by Players (2016-2021)
    Table 16. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neoantigen Cancer Vaccine as of 2020)
    Table 17. Ranking of Global Top Neoantigen Cancer Vaccine Companies by Revenue (US$ Million) in 2020
    Table 18. Global 5 Largest Players Market Share by Neoantigen Cancer Vaccine Revenue (CR5 and HHI) & (2016-2021)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Neoantigen Cancer Vaccine Product Solution and Service
    Table 21. Date of Enter into Neoantigen Cancer Vaccine Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
    Table 24. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2016-2021)
    Table 25. Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 26. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 27. Global Neoantigen Cancer Vaccine Market Size Share by Application (2016-2021) & (US$ Million)
    Table 28. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2016-2021)
    Table 29. Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 30. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 31. North America Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
    Table 32. North America Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
    Table 33. North America Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
    Table 34. North America Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
    Table 35. North America Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million) 
    Table 36. North America Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million) 
    Table 37. Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
    Table 38. Europe Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
    Table 39. Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
    Table 40. Europe Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
    Table 41. Europe Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million) 
    Table 42. Europe Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million) 
    Table 43. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
    Table 44. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
    Table 45. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2016-2021) & (US$ Million) 
    Table 48. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2022-2027) & (US$ Million) 
    Table 49. Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
    Table 50. Latin America Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
    Table 51. Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
    Table 52. Latin America Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
    Table 53. Latin America Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million) 
    Table 54. Latin America Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million) 
    Table 55. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
    Table 56. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
    Table 57. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million) 
    Table 60. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million) 
    Table 61. Roche Company Details
    Table 62. Roche Business Overview
    Table 63. Roche Neoantigen Cancer Vaccine Product
    Table 64. Roche Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 65. Roche Recent Development
    Table 66. Medimmune Company Details
    Table 67. Medimmune Business Overview
    Table 68. Medimmune Neoantigen Cancer Vaccine Product
    Table 69. Medimmune Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 70. Medimmune Recent Development
    Table 71. Merck Company Details
    Table 72. Merck Business Overview
    Table 73. Merck Neoantigen Cancer Vaccine Product
    Table 74. Merck Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 75. Merck Recent Development
    Table 76. Advaxis Company Details
    Table 77. Advaxis Business Overview
    Table 78. Advaxis Neoantigen Cancer Vaccine Product
    Table 79. Advaxis Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 80. Advaxis Recent Development
    Table 81. Agenus Company Details
    Table 82. Agenus Business Overview
    Table 83. Agenus Neoantigen Cancer Vaccine Product
    Table 84. Agenus Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 85. Agenus Recent Development
    Table 86. Genocea Company Details
    Table 87. Genocea Business Overview
    Table 88. Genocea Neoantigen Cancer Vaccine Product
    Table 89. Genocea Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 90. Genocea Recent Development
    Table 91. Gritstone Oncology Company Details
    Table 92. Gritstone Oncology Business Overview
    Table 93. Gritstone Oncology Neoantigen Cancer Vaccine Product
    Table 94. Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 95. Gritstone Oncology Recent Development
    Table 96. Neon Therapeutics Company Details
    Table 97. Neon Therapeutics Business Overview
    Table 98. Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 99. Neon Therapeutics Recent Development
    Table 100. Nouscom Company Details
    Table 101. Nouscom Business Overview
    Table 102. Nouscom Neoantigen Cancer Vaccine Product
    Table 103. Nouscom Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 104. Nouscom Recent Development
    Table 105. OSE Immunotherapeutics Company Details
    Table 106. OSE Immunotherapeutics Business Overview
    Table 107. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product
    Table 108. OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 109. OSE Immunotherapeutics Recent Development
    Table 110. Medigene Company Details
    Table 111. Medigene Business Overview
    Table 112. Medigene Neoantigen Cancer Vaccine Product
    Table 113. Medigene Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 114. Medigene Recent Development
    Table 115. Vaccibody Company Details
    Table 116. Vaccibody Business Overview
    Table 117. Vaccibody Neoantigen Cancer Vaccine Product
    Table 118. Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 119. Vaccibody Recent Development
    Table 120. Brightpath Biotherapeutics Company Details
    Table 121. Brightpath Biotherapeutics Business Overview
    Table 122. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product
    Table 123. Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 124. Brightpath Biotherapeutics Recent Development
    Table 125. Geneos Therapeutics Company Details
    Table 126. Geneos Therapeutics Business Overview
    Table 127. Geneos Therapeutics Neoantigen Cancer Vaccine Product
    Table 128. Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
    Table 129. Geneos Therapeutics Recent Development
    Table 130. Research Programs/Design for This Report
    Table 131. Key Data Information from Secondary Sources
    Table 132. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Neoantigen Cancer Vaccine Market Share by Type: 2020 VS 2027
    Figure 2. Personalized Vaccine Features
    Figure 3. Off-the-shelf Neovaccines Features
    Figure 4. Global Neoantigen Cancer Vaccine Market Share by Application: 2020 VS 2027
    Figure 5. Hospital Case Studies
    Figure 6. Clinic Case Studies
    Figure 7. Others Case Studies
    Figure 8. Neoantigen Cancer Vaccine Report Years Considered
    Figure 9. Global Neoantigen Cancer Vaccine Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 10. Global Neoantigen Cancer Vaccine Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global Neoantigen Cancer Vaccine Market Share by Regions: 2020 VS 2027
    Figure 12. Global Neoantigen Cancer Vaccine Market Share by Regions (2022-2027)
    Figure 13. Global Neoantigen Cancer Vaccine Market Share by Players in 2020
    Figure 14. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neoantigen Cancer Vaccine as of 2020
    Figure 15. The Top 10 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2020
    Figure 16. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2016-2021)
    Figure 17. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2022-2027)
    Figure 18. North America Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 19. North America Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
    Figure 20. North America Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
    Figure 21. North America Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
    Figure 22. United States Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 23. Canada Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 24. Europe Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 25. Europe Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
    Figure 26. Europe Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
    Figure 27. Europe Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
    Figure 28. Germany Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 29. France Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 30. U.K. Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 31. Italy Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. Russia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. Nordic Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Asia-Pacific Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
    Figure 36. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
    Figure 37. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Region (2016-2027)
    Figure 38. China Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 39. Japan Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 40. South Korea Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 41. Southeast Asia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. India Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. Australia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Latin America Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. Latin America Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
    Figure 46. Latin America Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
    Figure 47. Latin America Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
    Figure 48. Mexico Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 49. Brazil Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 50. Middle East & Africa Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 51. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
    Figure 52. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
    Figure 53. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
    Figure 54. Turkey Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 55. Saudi Arabia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 56. UAE Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 57. Roche Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 58. Medimmune Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 59. Merck Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 60. Advaxis Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 61. Agenus Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 62. Genocea Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 63. Gritstone Oncology Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 64. Neon Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 65. Nouscom Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 66. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 67. Medigene Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 68. Vaccibody Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 69. Brightpath Biotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 70. Geneos Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
    Figure 71. Bottom-up and Top-down Approaches for This Report
    Figure 72. Data Triangulation
    Figure 73. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Roche
Medimmune
Merck
Advaxis
Agenus
Genocea
Gritstone Oncology
Neon Therapeutics
Nouscom
OSE Immunotherapeutics
Medigene
Vaccibody
Brightpath Biotherapeutics
Geneos Therapeutics
Frequently Asked Questions
Neoantigen Cancer Vaccine report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Neoantigen Cancer Vaccine report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Neoantigen Cancer Vaccine report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Digital Biomarker

Digital biomarker refers to the use of modern computer technology for data collection and analysi ... Read More